Mike Ufer

2.7k total citations
67 papers, 1.9k citations indexed

About

Mike Ufer is a scholar working on Pharmacology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Mike Ufer has authored 67 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 13 papers in Molecular Biology and 12 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Mike Ufer's work include Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (10 papers) and Antiplatelet Therapy and Cardiovascular Diseases (7 papers). Mike Ufer is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (10 papers) and Antiplatelet Therapy and Cardiovascular Diseases (7 papers). Mike Ufer collaborates with scholars based in Switzerland, Germany and Sweden. Mike Ufer's co-authors include Jasper Dingemanse, Anders Rane, Elin Kimland, Ingolf Cascorbi, Sierk Haenisch, Ulf Bergman, Bernd Kammerer, Pierre‐Éric Juif, Rainer Kahlich and Julia Kirchheiner and has published in prestigious journals such as Journal of the American College of Cardiology, Neurology and Analytical Biochemistry.

In The Last Decade

Mike Ufer

66 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mike Ufer Switzerland	25	429	399	381	331	273	67	1.9k
Nita A. Limdi United States	25	795 1.9×	443 1.1×	193 0.5×	90 0.3×	369 1.4×	94	2.4k
Inge De Lepeleire United States	28	391 0.9×	101 0.3×	207 0.5×	110 0.3×	278 1.0×	80	2.4k
Hermann R. Ochs United States	30	582 1.4×	409 1.0×	553 1.5×	313 0.9×	366 1.3×	117	2.8k
Caterina Palleria Italy	21	141 0.3×	224 0.6×	158 0.4×	125 0.4×	255 0.9×	75	1.5k
Georg Engel Germany	14	88 0.2×	128 0.3×	291 0.8×	251 0.8×	522 1.9×	31	1.6k
Céline Verstuyft France	36	1.4k 3.2×	1.0k 2.5×	1.2k 3.1×	1.0k 3.1×	487 1.8×	131	4.8k
Robert B. Parker United States	27	375 0.9×	127 0.3×	271 0.7×	168 0.5×	779 2.9×	100	2.6k
Jan de Hoon Belgium	35	180 0.4×	1.0k 2.6×	293 0.8×	411 1.2×	310 1.1×	180	3.6k
D. Loew Germany	22	216 0.5×	94 0.2×	258 0.7×	90 0.3×	284 1.0×	106	1.7k
Maria Gabriella Scordo Italy	25	118 0.3×	386 1.0×	1.0k 2.7×	308 0.9×	219 0.8×	32	2.1k

Countries citing papers authored by Mike Ufer

Since Specialization

Citations

This map shows the geographic impact of Mike Ufer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Ufer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Ufer more than expected).

Fields of papers citing papers by Mike Ufer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike Ufer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Ufer. The network helps show where Mike Ufer may publish in the future.

Co-authorship network of co-authors of Mike Ufer

This figure shows the co-authorship network connecting the top 25 collaborators of Mike Ufer. A scholar is included among the top collaborators of Mike Ufer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike Ufer. Mike Ufer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abbara, Ali, Mike Ufer, Lance Berman, et al.. (2023). Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals. Fertility and Sterility. 121(1). 95–106. 7 indexed citations

Huynh, Christine, Daniel S. Strasser, Mohamed Al‐Ibrahim, et al.. (2021). A Multipurpose First‐in‐Human Study With the Novel CXCR7 Antagonist ACT‐1004‐1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker. Clinical Pharmacology & Therapeutics. 109(6). 1648–1659. 9 indexed citations

Muehlan, Clemens, et al.. (2021). Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis. Clinical Drug Investigation. 41(8). 711–721. 16 indexed citations

Juif, Pierre‐Éric, Jasper Dingemanse, & Mike Ufer. (2021). Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm. Frontiers in Pharmacology. 11. 628956–628956. 16 indexed citations

Sinnaeve, Peter, Gregor Fahrni, Alessandro Spirito, et al.. (2020). Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology. 75(20). 2588–2597. 57 indexed citations

Storey, Robert F., Paul A. Gurbel, Jurriën M. ten Berg, et al.. (2019). Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal. 41(33). 3132–3140. 51 indexed citations

Halabi, Atef, et al.. (2019). Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects. European Journal of Clinical Pharmacology. 76(3). 431–437. 7 indexed citations

Jin, Yi, et al.. (2017). In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. European Journal of Clinical Pharmacology. 74(4). 455–464. 23 indexed citations

Ufer, Mike, Alexandros Sagkriotis, Ganesan Subramanian, et al.. (2016). Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056). Clinical Therapeutics. 38(12). 2589–2597. 2 indexed citations

10.

Jacquemont, Sébastien, Elizabeth Berry‐Kravis, Randi J. Hagerman, et al.. (2013). The challenges of clinical trials in fragile X syndrome. Psychopharmacology. 231(6). 1237–1250. 91 indexed citations

11.

Ufer, Mike, Celina von Stülpnagel, Hiltrud Muhle, et al.. (2011). Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenetics and Genomics. 21(10). 624–630. 43 indexed citations

12.

Afsar, Nasir Ali, Mike Ufer, Sierk Haenisch, et al.. (2011). Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. European Journal of Clinical Pharmacology. 68(4). 389–395. 29 indexed citations

13.

Ufer, Mike. (2010). Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thrombosis and Haemostasis. 103(3). 572–585. 94 indexed citations

14.

Ufer, Mike, Hiltrud Muhle, Sierk Haenisch, et al.. (2009). Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 −24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenetics and Genomics. 19(5). 353–362. 83 indexed citations

15.

Ufer, Mike, Olaf Junge, Gisbert Selke, et al.. (2007). Patterns and prevalence of antidepressant drug use in the German state of Baden‐Wuerttemberg: a prescription‐based analysis. Pharmacoepidemiology and Drug Safety. 16(10). 1153–1160. 29 indexed citations

16.

Renders, Lutz, Mike Ufer, Igor Mosyagin, et al.. (2006). CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients. Clinical Pharmacology & Therapeutics. 81(2). 228–234. 107 indexed citations

17.

Ufer, Mike, Anja Vogt, Goran Palčevski, et al.. (2005). Antimicrobial drug use in hospitalised paediatric patients: a cross-national comparison between Germany and Croatia. Pharmacoepidemiology and Drug Safety. 14(10). 735–739. 18 indexed citations

18.

Ufer, Mike. (2005). Comparative Pharmacokinetics of Vitamin K Antagonists. Clinical Pharmacokinetics. 44(12). 1227–1246. 238 indexed citations

19.

Ufer, Mike, Elin Kimland, & Ulf Bergman. (2003). Adverse drug reactions and off‐label prescribing for paediatric outpatients: a one‐year survey of spontaneous reports in Sweden. Pharmacoepidemiology and Drug Safety. 13(3). 147–152. 62 indexed citations

20.

Ufer, Mike, et al.. (2003). Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. European Journal of Clinical Pharmacology. 58(11). 779–783. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact